Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CXCL17 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA567712
Description
CXCL17 Polyclonal Antibody for Western Blot
CXCL17 is a chemokine that acts as chemoattractant for monocytes, macrophages and dendritic cells. In particular, CXCL17 is a mucosal chemokine that attracts dendritic cells and blood monocytes to the lungs. CXCL17 plays a role in angiogenesis and possibly in the development of tumors. Further, CXCL17 acts as an anti-inflammatory in the stomach and may play a role in the innate defense against infections. CXCL17 also activates the C-X-C chemokine receptor GPR35 to induce a rapid and transient rise in the level of intracellular calcium ions. 4-Cys CXCL17 seems to exhibit much higher chemoattractant potency on monocytes and macrophages than 6-Cys CXCL17. Diseases associated with CXCL17 dysfunction include cholera.
Specifications
CXCL17 | |
Polyclonal | |
Unconjugated | |
CXCL17 | |
13.6 kDa protein; 13.6-kDa protein; 4-Cys CXCL17; 6-Cys CXCL17; C Cmotif chemokine; C X C motif chemokine; CC motif chemokine; CCmotif chemokine; chemokine (C-X-C motif) ligand 17; CXC; CXC motif chemokine; C-X-C motif chemokine 17; C-X-C motif chemokine ligand 17; CXCL; CXCL17; Dcip1; Dendritic cell and monocyte chemokine-like protein; DMC; UNQ473; UNQ473/PRO842; Vcc1; VCC-1; VEGF coregulated chemokine 1; VEGF co-regulated chemokine 1 | |
Rabbit | |
Affinity Chromatography | |
RUO | |
284340 | |
-20°C | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q6UXB2 | |
CXCL17 | |
Synthesized peptide derived from human CXCL17. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction